Abstract 3021

The combination of lenalidomide and dexamethasone can produce partial and complete hematologic responses in previously treated patients with AL amyloidosis (Blood 2007; 109: 492–496). Since this prospective study was initiated, NT-proBNP and BNP have been found to be useful biomarkers for cardiac involvement, prognosis, and response to therapy in AL amyloidosis patients. Here we report on the retrospective analysis of the prospectively collected data on changes in BNP during lenalidomide therapy on this trial. Increase in BNP was defined as > 30% increase from baseline value at enrollment on the trial after cycles 1 and 3. Patients with BNP of < 100 pg/mL at baseline, and after 1 and 3 cycles as well as patients in whom BNP levels were not measured were excluded in this analysis. Sixty-eight patients with AL amyloidosis were treated with lenalidomide and dexamethasone (ClinicalTrials.gov: NCT00091260) at Boston Medical Center. The median age was 64 years (range, 42 to 85); and 69% were male. Fifty-one patients (75%) had lambda clonal plasma cell dyscrasia, and 38 (56%) had cardiac involvement. All patients received lenalidomide and dexamethasone as described in our previous report. Twenty-four of the 68 total patients enrolled did not meet the eligibility to be included in this analysis due to either BNP levels of < 100 pg/mL at baseline and at 1 and 3 months after treatment or unavailability of BNP measurement after 1 or 3 cycles of lenalidomide. Therefore, 44 patients are included in this analysis. Thirty-eight patients (86%) had > 30% increase in BNP level from baseline after initiation of lenalidomide treatment. Of these 38 patients, 30 (79%) had an increase after 1 cycle and additional 8 (21%) patients after 3 cycles of lenalidomide. The mean dose of lenalidomide for patients with increase in BNP after 1 cycle was 15 mg (range, 5–25) and after 3 cycles was 10 mg (range, 5–15). Forty % (n=12/30) and 63% (n=5/8) of patients did not receive dexamethasone with lenalidomide when increase in BNP was seen after 1 and 3 cycles, respectively. Of the patients with increase in BNP, only 5 patients (13%) had worsening of renal function from baseline. Moreover, increase in BNP after 1 and 3 cycles occurred in 23 of 29 patients (79%) with cardiac involvement. Cardiac troponin I levels were not measured after 1 and 3 cycles of lenalidomide. All the patients with increase in BNP were asymptomatic without association of modification in NYHA class congestive heart failure. The median survival of these 44 patients is 53 months since initiation of lenalidomide therapy. At these early time pointsof 1 and 3 months, 20% (n=9/44) of patients had >50% improvement in serum free light chain levels, and 2% (n=1/44) of patients had improvement in BNP of 30% or more. In conclusion, BNP increased by > 30% in a substantial proportion of patients with AL amyloidosis during treatment with lenalidomide. The mechanism for asymptomatic rise in BNP is not clear; however, the temporal relationship with lenalidomide initiation, the relatively rapid increase, and the absence of other identifiable precipitants for most of the patients suggest that lenalidomide may be playing a role. Moreover, patients with AL amyloidosis receiving lenalidomide whose BNP rises should not be assumed to be failing therapy without other signs of disease progression, but should be monitored closely and treated as needed for signs or symptoms of congestive heart failure should they occur.


Off Label Use: Use of lenalidomide in AL amyloidosis. Zeldis:Celgene Corp: Employment.

Author notes


Asterisk with author names denotes non-ASH members.